TOKUSHIMA, Japan–(BUSINESS WIRE)–Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML).
Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval.
DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients� enrollment plan soon.
Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families.
| Company profile | |
| Company name | Delta-Fly Pharma, Inc. [Tokyo:4598] |
| Capital | 3352 million Japanese Yen |
| Name and Title of Representative | Kiyoshi Eshima, PhD, President |
| Date of Incorporation | December 6, 2010 |
| Description of Business | Research and development, manufacturing and marketing of pharmaceuticals |
| Head Office | 37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan |
| Branch Office | Tokyo, Beijing, Vancouver |
Contacts
Delta-Fly Pharma, Inc.
Inquiries: Yasuo Matsueda
TEL: +81-(0)3-6231-1278
ymatsueda1206@delta-flypharma.co.jp
https://www.delta-flypharma.co.jp/en/
QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…
SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…
DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…
Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…
EAST BRUNSWICK, N.J. & BENGALURU, India--(BUSINESS WIRE)--$WIPRO #AIprinciples--Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO),…
THOMASVILLE, Ga.--(BUSINESS WIRE)--Cleaver-Brooks announces that it has been acquired by Miura Co., Ltd., a leading…
